FDA expands use of Gilead's liver drug to rare subset of patients
0
(Reuters) - The U.S. Food and Drug Administration has expanded the use of Gilead Sciences Inc's blockbuster drug Harvoni to some hepatitis C patients in the advanced stage of cirrhosis, including those who have undergone liver transplant.